Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ARID1A del |
| Therapy | Capivasertib |
| Indication/Tumor Type | stomach cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ARID1A del | stomach cancer | sensitive | Capivasertib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Truqap (capivasertib) inhibited proliferation and colony formation in an ARID1A knockout gastric cancer cell line in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 39003371). | 39003371 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39003371) | The AKT inhibitor AZD5363 elicits synthetic lethality in ARID1A-deficient gastric cancer cells via induction of pyroptosis. | Full reference... |